Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL) is a healthcare company (diagnostics & research) based in the United States. The share price is $334.83, down 0.21% on the day, which values the company at $16.04B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.

Key facts

Share price
$334.83−0.21% today
Market value
$16.04B
P/E ratio
363.9×last 12 months
Forward P/E
25.8×
Funk Score
38/100
Against its own history
Well above its usual priceusual price $195.55
200-week average
$201.9366% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Charles River Laboratories International, Inc. in more detail

CRL trades at 363.9× its last twelve months' earnings, 25.8× next year's expected earnings, 4.0× sales. Measured against its own history, the price is 71% above what its usual multiples would imply ($195.55) — well above its usual price. It sits 66% above its 200-week average of $201.93.

Over the last five fiscal years Charles River Laboratories International, Inc. has compounded revenue 6.5% a year, free cash flow 6.4% a year. Its Funk Score is 38 out of 100 (financial strength 3.8, profitability 4.0, growth 3.8, value 3.5, each out of 10).

In its favour: Altman Z in the safe zone.

7 of the superinvestors tracked here hold CRL, including John Rogers (3.7% of the portfolio), Anthony Bozza (0.9% of the portfolio), Bill Nygren (0.7% of the portfolio).

Superinvestors holding CRL

7 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:CRL vs NBIX (Charles River Laboratories International, Inc. vs Neurocrine Biosciences)CRL vs EXEL (Charles River Laboratories International, Inc. vs Exelixis)CRL vs ASND (Charles River Laboratories International, Inc. vs Ascendis Pharma)CRL vs RVTY (Charles River Laboratories International, Inc. vs Revvity)CRL vs MEDP (Charles River Laboratories International, Inc. vs Medpace Holdings)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Charles River Laboratories International, Inc. (CRL): questions and answers

What is CRL's P/E ratio?

Charles River Laboratories International, Inc. trades at 363.9× its last twelve months' earnings and 25.8× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 12.8× to 49.6×, with a median of 24.8×.

What is CRL's PEG ratio?

Charles River Laboratories International, Inc.'s PEG ratio is 0.12 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Charles River Laboratories International, Inc.'s market cap?

Charles River Laboratories International, Inc. is valued at $16.04B at a share price of $334.83.

Is CRL overvalued or undervalued?

Against its own history, CRL is well above its usual price: the price is 71% above the $195.55 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CRL above its 200-week moving average?

Yes. CRL is 65.8% above its 200-week average of $201.93. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Charles River Laboratories International, Inc. growing?

Over the last five fiscal years Charles River Laboratories International, Inc.'s revenue grew 6.5% a year; over ten years revenue grew 11.4% a year.

Cite this page

Funkfolio, “Charles River Laboratories International, Inc. (CRL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CRL

Underlying data: Yahoo Finance; company filings with the SEC.